Navigant Pathogen Inactivation System Catching Up With Cerus, Vitex
This article was originally published in The Gray Sheet
Executive Summary
Navigant Biotechnologies is dedicating $10 mil. in 2004 to the development of its Mirasol riboflavin-based pathogen reduction technology (PRT) for platelets and red blood cells